deltatrials
Completed PHASE4 INTERVENTIONAL 1-arm NCT04783935

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

A 2-year Extension Study to Evaluate Long-term Effectiveness of Mavenclad® in Participants Who Have Completed Trial MS700568_0022 (MAGNIFY MS) (Magnify MS Extension)

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Interventions Mavenclad®
Updated 12 times since 2021 Last updated: Dec 9, 2024 Started: Mar 10, 2021 Primary completion: Sep 21, 2023 Completion: Sep 21, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Multiple Sclerosis and is currently completed. Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany leads this study, which shows 12 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshotRecruiting~Dec 2022 – ~Jul 2023 · 7 months · monthly snapshotActive Not Recruiting~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshotCompleted~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshotCompleted~Sep 2025 – present · 9 months · monthly snapshotCompleted

Change History

12 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE4

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. May 2024 — Jul 2024 [monthly]

    Completed PHASE4

    Status: Active Not RecruitingCompleted

Show 7 earlier versions
  1. Mar 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE4

  2. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE4

  3. Jul 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE4

  4. Dec 2022 — Jul 2023 [monthly]

    Active Not Recruiting PHASE4

    Status: RecruitingActive Not Recruiting

  5. Sep 2021 — Dec 2022 [monthly]

    Recruiting PHASE4

  6. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE4

    Status: Not Yet RecruitingRecruiting

  7. Apr 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Data source: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .